חוב כולל להון Marker Therapeutics (MRKR)

Marker Therapeutics (MRKR) is currently experiencing a period of financial deficit due to medical testing costs, creating a need for capital. This chart shows the market price on GURU.Markets for the total debt-to-equity ratio is 0.00, while the business implements energy-efficient technologies and waste treatment. The development of blood treatments remains independent of economic cycles, relying exclusively on scientific achievements.

Marker Therapeutics focuses on clinical trials for blood cancer therapies, operating on previously raised funds in the absence of operating income. The leverage ratio, which compares total liabilities to equity, allows for an assessment of the degree of financial leverage and bankruptcy risks, which, combined with the historical debt-to-equity ratio, helps investors monitor the company's stability during its pre-profit stage.